MACH7 TECHNOLOGIES LIMITED — Director's Dealing 2024

Aug 14, 2024

ASX Announcement

15 August 2024

==> picture [104 x 5] intentionally omitted <==

==> picture [104 x 5] intentionally omitted <==

==> picture [104 x 5] intentionally omitted <==

==> picture [104 x 5] intentionally omitted <==

==> picture [104 x 6] intentionally omitted <==

==> picture [104 x 5] intentionally omitted <==

AMENDMENT TO APPENDIX 3Y – CHANGE TO DIRECTOR’S INTEREST NOTICE FOR DR ELIOT SIEGEL

Mach7 Technologies Limited (“M7T” or “the Company”) (ASX:M7T) advises that during a review it was noted that the Appendix 3Y for Dr Eliot Siegel lodged on 1 December 2023 contained a clerical error in that the “Number of securities held prior to change” included an incorrect carry-forward balance of options. A corrected Appendix 3Y, which replaces the Appendix 3Y lodged on 1 December 2023, is attached.

This announcement has been authorised for release by the Company Secretary, Tony Panther.

For more information, contact:

Investor Relations

Françoise Dixon +61 (0) 412 292 977 ir@mach7t.com

About Mach7 Technologies

Mach7 Technologies (ASX:M7T), founded in 2007, is a medical imaging systems provider that develops innovative image management and viewing solutions for healthcare organizations. The core of these offerings is the Mach7 Enterprise Imaging Solution, encompassing Enterprise Data Management, Enterprise Diagnostic Viewing and Departmental Workflow applications. Mach7’s Enterprise Data Management solution, consisting of a powerful Vendor Neutral Archive (VNA) and data administration tools, allows for the fast storage, access, retrieval and viewing of images across a healthcare network with connectivity to the Cloud. In July 2020, Mach7 acquired Client Outlook and the eUnity Enterprise Diagnostic Viewing technology to augment Mach7’s Enterprise Data Management and Departmental Workflow applications. eUnity is a zerofootprint, FDA-approved, image viewing solution that makes images accessible on any workstation. This offers healthcare professionals consolidated access to all patient images and data, ensuring radiologists and clinical staff have timely access to the right information to diagnose and treat patients. Uniquely, the company also gives customers independence to deploy its solutions either on a component basis or in a unified comprehensive platform. With more than 165 customers across 15 different countries, Mach7 has built a global network of diverse customers that range from expansive Integrated Delivery Networks, National Health Systems, medical research facilities, and large academic medical institutions to regional community hospitals, private radiology practices, and independent provider groups. Visit Mach7t.com.

==> picture [150 x 12] intentionally omitted <==

==> picture [150 x 11] intentionally omitted <==

==> picture [150 x 12] intentionally omitted <==

==> picture [150 x 11] intentionally omitted <==

==> picture [150 x 12] intentionally omitted <==

Mach7 Technologies Limited (ASX:M7T) ABN: 26 007 817 192 Registered Office: Level 4, 96 – 100 Albert Road, South Melbourne, VIC 3205 T: 03 9692 7222 www.mach7t.com

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Mach7 Technologies Limited

ABN: 26 007 817 192

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Eliot Siegel
Date of last notice	6 November 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	1 December 2023
No. of securities held prior to change	100,000 unlisted options 246,100 Fully Paid Ordinary Shares
Class	Unlisted Options
Number acquired	25,000 Unlisted Options
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	125,000 unlisted options 246,100 Fully Paid Ordinary Shares

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Issue of Options under the Mach7 Long Example: on-market trade, off-market trade, exercise of options, issue Term Incentive Plan as approved at of securities under dividend reinvestment plan, participation in buyback Annual General Meeting held 16 November 2023.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011